(ARMP)
ASE – Real Time Price. Currency in USD
8.37
-0.98 (-10.48%)
At close: Mar 27, 2026, 4:00 PM EDT
8.21
-0.16 (-1.91%)
After-hours: Mar 27, 2026, 6:27 PM EDT
Get all premium features to the best stock analysis tool
ASE – Real Time Price. Currency in USD
8.37
-0.98 (-10.48%)
At close: Mar 27, 2026, 4:00 PM EDT
8.21
-0.16 (-1.91%)
After-hours: Mar 27, 2026, 6:27 PM EDT
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
| Name | Position |
|---|---|
| Dr. Deborah L. Birx M.D. | CEO & Director |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
| Mr. David D. House | Senior VP of Finance & Principal Financial Officer |
| Mr. Peter Hubbard | Vice President of Operations |
| Ms. Bani Tchekanova Ph.D. | Head of Regulatory Strategy & Operations |
| Date | Type | Document |
|---|---|---|
| 2026-01-26 | 8-K | tm263967d1_8k.htm |
| 2026-01-13 | 8-K | tm262898d1_8k.htm |
| 2025-12-01 | 8-K | tm2532031d2_8k.htm |
| 2025-11-12 | 10-Q | armp-20250930x10q.htm |
| 2025-10-22 | 8-K | tm2529060d1_8k.htm |
| 2025-09-11 | 8-K | tm2525814d1_8k.htm |
| 2025-08-13 | S-3 | tm2523066d1_s3.htm |
| 2025-08-12 | 10-Q | armp-20250630x10q.htm |
| 2025-06-13 | 8-K | tm2517977d1_8k.htm |
| 2025-05-19 | 8-K | tm2515395d1_8k.htm |